Unknown

Dataset Information

0

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma

ABSTRACT:

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC8798318 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
| S-EPMC6716603 | biostudies-literature
Unknown Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
| S-EPMC7060483 | biostudies-literature
Unknown A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma.
| S-EPMC7225300 | biostudies-literature
Unknown Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
| S-EPMC8493486 | biostudies-literature
Unknown Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
| S-EPMC8436592 | biostudies-literature
Unknown Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
| S-EPMC8099757 | biostudies-literature
Unknown Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
| S-EPMC5972549 | biostudies-literature
Unknown Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
| S-EPMC8436591 | biostudies-literature
Unknown Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
| S-EPMC7873332 | biostudies-literature
Unknown Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
| S-EPMC7557509 | biostudies-literature